Best responses after first 2 cycles of blinatumomab treatment in patients with high-risk and low-risk genetic abnormalities
| . | n (%) . |
|---|---|
| High-risk genetic abnormalities | |
| Constitutional trisomy (n = 4) | |
| CR with MRD | 4 (100) |
| t(17;19)/TCF3-HLF (n = 2) | |
| CR with MRD | 2 (100) |
| MLL rearrangement (n = 18) | |
| CR with MRD | 4 (22) |
| CR without MRD | 2 (11) |
| PD | 7 (39) |
| SD | 2 (11) |
| Noncompletion of at least 1 blinatumomab cycle | 2 (11) |
| Inevaluable* | 1 (6) |
| t(9;22)/BCR-ABL (n = 5) | |
| CR with MRD | 2 (40) |
| CR without MRD | 2 (40) |
| PD | 1 (20) |
| Low-risk genetic abnormalities | |
| t(12;21)/TEL-AML1 (n = 9) | |
| CR with MRD | 5 (56) |
| CR without MRD | 1 (11) |
| Noncompletion of at least 1 blinatumomab cycle | 2 (22) |
| PD | 1 (11) |
| Hyperdiploidy (n = 6) | |
| CR with MRD | 2 (33) |
| CR without MRD | 2 (33) |
| PD | 2 (33) |
| . | n (%) . |
|---|---|
| High-risk genetic abnormalities | |
| Constitutional trisomy (n = 4) | |
| CR with MRD | 4 (100) |
| t(17;19)/TCF3-HLF (n = 2) | |
| CR with MRD | 2 (100) |
| MLL rearrangement (n = 18) | |
| CR with MRD | 4 (22) |
| CR without MRD | 2 (11) |
| PD | 7 (39) |
| SD | 2 (11) |
| Noncompletion of at least 1 blinatumomab cycle | 2 (11) |
| Inevaluable* | 1 (6) |
| t(9;22)/BCR-ABL (n = 5) | |
| CR with MRD | 2 (40) |
| CR without MRD | 2 (40) |
| PD | 1 (20) |
| Low-risk genetic abnormalities | |
| t(12;21)/TEL-AML1 (n = 9) | |
| CR with MRD | 5 (56) |
| CR without MRD | 1 (11) |
| Noncompletion of at least 1 blinatumomab cycle | 2 (22) |
| PD | 1 (11) |
| Hyperdiploidy (n = 6) | |
| CR with MRD | 2 (33) |
| CR without MRD | 2 (33) |
| PD | 2 (33) |
PD, progressive disease; SD, stable disease.
Bone marrow assessment was not performed because of poor health of the patient after the first blinatumomab cycle.